对于成年人抑郁症的伏尔托克塞丁:随机对照试验的系统综述和剂量反应元分析
Xin Yang1, Shuping Fang1, Wenqi Lyu1
1Department of Mental Health Center, West China Hospital of Sichuan University, Chengdu, China.
Psychiatry and clinical neurosciences
|July 3, 2024
概括
较高剂量的西可能为严重抑郁症 (MDD) 提供更大的益处,而不会显著增加风险. 需要进行进一步的试验,以探索MDD治疗目前批准的剂量之外的疗效和安全性.
科学领域:
- 精神病学和药理学 精神病学和药理学
- 临床研究 临床研究
- 证据综合 证据综合
背景情况:
- 大型抑郁症 (MDD) 是一种常见的心理健康状况.
- 伏尔托克塞丁是一种抗抑郁药,具有独特的药理学特征.
- 在MDD中,西的剂量反应关系需要进一步阐明.
研究的目的:
- 为了对MDD进行伏尔托克塞丁的剂量反应元分析.
- 为了确定vortioxetine的剂量-有效性和剂量-安全性关系.
- 为了确定MDD治疗中西的最佳剂量策略.
主要方法:
- 系统搜索MDD中西的随机对照试验 (RCT).
- 一阶段随机效应剂量反应元分析,使用受限立方线.
- 主要结局:疗效 (抑郁症等级得分的变化);次要结局:反应率,可接受性,耐受性和安全性.
主要成果:
- 分析包括了16项研究,其中4,294名参与者接受了西,2,299名参与者接受安慰剂.
- 估计50%的有效剂量为4.37毫克/天,95%的有效剂量为17.93毫克/天.
- 疗效可能会继续增加超过20毫克/天,而可接受性,耐受性和安全性会随着剂量增加而下降,尽管亚组分析显示没有显著差异.
结论:
- 在剂量超过当前许可范围时,沃尔提奥塞丁可能会提供额外的治疗益处.
- 超过目前已批准的伏尔托克塞丁剂量可能会提高疗效,而不会显著地影响安全性.
- 需要进行进一步的临床试验,研究更高剂量的伏尔西,以充分评估其在MDD中的疗效和风险概况.
相关概念视频
01:05Long-term Depression
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
01:18Depression: Overview
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...